Biotech's Double Standard: What Brinsupri's Success Means for Mirum's Misfortune The biotech sector's recent surge in Insmed stock, driven by the success of its lung disease drug Brinsupri, raises questions about the industry's ability to separate actual innovation from overhyped expectations.
Brinsupri has exceeded sales projections, generating $309. 2 million against forecasts of $276. 6 million.
The contrast between Insmed's triumphant Brinsupri launch and Mirum's decline serves as a stark reminder that biotech's fortunes are volatile and unpredictable.